GLP1R and Ventricular arrhythmia: Despite advancements in the management of ventricular arrhythmias (VA), these cardiac conditions remain a leading cause of cardiovascular morbidity and sudden cardiac death, accounting for up to 300 000 deaths annually in the United States.1 Emerging clinical trial evidence has demonstrated a role for glucagon-like peptide-1 (GLP-1) receptor agonists in improving cardiovascular outcomes.